Pharmacokinetics of Risankizumab in Asian Healthy Subjects and Patients With Moderate to Severe Plaque Psoriasis, Generalized Pustular Psoriasis, and Erythrodermic Psoriasis-Reference-Cited by-同舟云学术

Pharmacokinetics of Risankizumab in Asian Healthy Subjects and Patients With Moderate to Severe Plaque Psoriasis, Generalized Pustular Psoriasis, and Erythrodermic Psoriasis

Published:2019-06-30 Issue:12 Volume:59 Page:1656-1668
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:The Journal of Clinical Pharmacology

Author:

Khatri Amit¹,Eckert Doerthe²,Oberoi Rajneet¹,Suleiman Ahmed²,Pang Yinuo¹,Cheng Ling³,Othman Ahmed A.¹^ORCID

Affiliation:

1. Clinical Pharmacology and Pharmacometrics, AbbVie Inc. North Chicago IL USA

2. Clinical Pharmacology and PharmacometricsAbbVie Deutschland GmbH & Co KG Ludwigshafen am Rhein Germany

3. Discovery and Exploratory Statistics, AbbVie Inc North Chicago IL USA

Funder

Boehringer Ingelheim

AbbVie

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jcph.1473

Reference16 articles.

1. Psoriasis: from Pathogenesis to Targeted Therapies

2. Generalized pustular psoriasis: a review and update on treatment

3. Erythrodermic psoriasis: pathophysiology and current treatment perspectives;Singh RK;Psoriasis (Auckl),2016

4. The IL-23–IL-17 immune axis: from mechanisms to therapeutic testing

5. Selective targeting of the IL23 pathway: Generation and characterization of a novel high-affinity humanized anti-IL23A antibody

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and Pharmacokinetics of Single‐Dose Mirikizumab in Chinese Healthy Participants: Results From a Phase 1 Study;Clinical Pharmacology in Drug Development;2024-09-04

2. Inter-Antibody Variability in the Clinical Pharmacokinetics of Monoclonal Antibodies Characterized Using Population Physiologically Based Pharmacokinetic Modeling;Antibodies;2024-07-09

3. Formation and clinical effects of anti-drug antibodies against biologics in psoriasis treatment: An analysis of current evidence;Autoimmunity Reviews;2024-04

4. Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Moderate-to-Severe Psoriasis;Clinical Pharmacokinetics;2024-01-27

5. Treatment patterns and drug survival for generalized pustular psoriasis: A patient journey study using a Japanese claims database;The Journal of Dermatology;2024-01-12